DEC 18, 2016 7:06 AM PST

Leukemia Stunted into Remission via Fasting

WRITTEN BY: Xuan Pham

The newest leukemia research findings suggest that intermittent fasting may literally starve the cancer cells too. The study, by the University of Texas Southwestern Medical Center, explores different pathways by which acute lymphoblastic leukemia may be targeted more successfully.

Image credit: Pixabay.com

Though considered a rare disease, acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer, peaking in early childhood between the ages of 2 and 4. The cancer involves the overproduction of immature white blood cells in the bone marrow. These cancerous cells invade the blood and other organ systems, causing massive cell death and damage in a short amount of time.

Fortunately, doctors have an arsenal of weapons that are effective against ALL. These include radiation therapy, bone marrow transplantation, and chemotherapy agents like methotrexate, vincristine, and cytarabine. With treatment, the 5-year survival rate for the majority of ALL patients is 70 percent. However, remission isn’t a sustained outcome in 15 to 20 percent of children in whom the cancer makes a dreaded comeback.

Based on previous research that suggests fasting may augment chemotherapy outcome, researchers at UT Southwestern decided to investigate this line of treatment in several mouse models of ALL. The mice received either normal feeding or were subject to a dietary restriction consistent with intermittent fasting.

"Strikingly, we found that in models of ALL, a regimen consisting of six cycles of 1 day of fasting followed by 1 day of feeding completely inhibited cancer development," reported Chengcheng Zhang, associate professor at UT Southwestern, and the study’s lead author.

Within 7 weeks on the fasting diet, the mice had undetectable levels of leukemia cells in the bone marrow and spleen, a promising sign of disease remission. By contrast, mice on the normal diet regimen contained nearly 70 percent of cancerous cells in the affected organs.

"Although initially cancerous, the few fluorescent cells that remained in the fasted mice after 7 weeks appeared to behave like normal cells. Mice in the ALL model group that ate normally died within 59 days, while 75 percent of the fasted mice survived more than 120 days without signs of leukemia,” reported Zhang.

The exact mechanism behind this effect is yet to be fully understood. However, Zhang’s team suspect it involves leptin, a “satiety hormone” released to inhibit the hunger sensation. "We found that fasting decreased the levels of leptin circulating in the bloodstream as well as decreased the leptin levels in the bone marrow," said Zhang. "These effects became more pronounced with repeated cycles of fasting," he adds. "After fasting, the rate at which the leptin levels recovered seemed to correspond to the rate at which the cancerous ALL cells were cleared from the blood."

While the results have big implications for leukemia research and treatment, fasting as a treatment for ALL has still yet to be tested in human clinical trials. And until such trial delivers the same promising results, patients or caretakers should not yet consider fasting as a treatment plan.

Additional sources: MNT 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 22, 2019
Cancer
NOV 22, 2019
The cancerous fear of circular extrachromosomal DNA
New research published in Nature suggests that ring-shaped extrachromosomal DNA (ecDNA) is particularly abundant in tumor cells and plays a malicious role ...
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Making T-Cell Therapy Even More Effective
Curated w/video - CRISPR/Cas9 deletion of an enzyme resulted in longer lasting, more robust therapy....
JAN 02, 2020
Drug Discovery & Development
JAN 02, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
FEB 10, 2020
Immunology
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
Loading Comments...